KAT5 and squamous cell carcinoma: Thus, our findings underscore the reported specificity of TH1834 for TIP60 inhibition and suggest it would have fewer off-target effects than alternatives like NU9056 in the treatment of cisplatin-resistant squamous cell carcinoma (SCC).